An interventional study of ABLE Exoskeleton in Multiple Sclerosis, sponsored by ABLE Human Motion S.L.. Completed at 1 site in Spain. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-07-31.
Sponsored by ABLE Human Motion S.L. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 230 studies in Multiple Sclerosis with a site in Spain — 35 open to participants now, 56 under way, 14 of them phase 3. Multiple Sclerosis · Spain.
Among the 230 studies in Multiple Sclerosis with a site in Spain, this one is the 154th largest by enrollment of the 202 interventional ones that give a count, is one of 18 that started in 2024, is one of 68 with no phase, and was the 179th registered.
3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →35 of the 230 studies in Multiple Sclerosis with a site in Spain are open now. Recruiting first, the newest first:
Clarity Health Technologies, Inc · Sites in Spain
Ages 18–65
Sanofi · Sites in Spain, United States, Belgium and 4 more countries
Ages 18–60
Novartis Pharmaceuticals · Sites in Spain, United States, Argentina and 33 more countries
Ages 18–65
Hasselt University · Sites in Spain, Belgium, Italy
Ages 18–65 · Healthy volunteers
Hoffmann-La Roche · Sites in Spain, Argentina, Brazil and 4 more countries
Ages 10–17
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
230 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 47 · Phase 3 65 · Phase 4 17
First in 2002; this study’s year is marked. 18 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 33 is below the median of 50 across 2,208 interventional studies indexed under Multiple Sclerosis.
Median enrollment 137 across the 202 interventional studies, 360 across the 28 observational. Of the 163 that completed or were terminated, 80 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
142 of 230 have an industry lead sponsor. The 10 most frequent:
ABLE Human Motion S.L. is the lead sponsor of 11 studies on the registry; 2 are open to participants now.
ABLE Human Motion S.L. has 3 studies filed under Multiple Sclerosis — fewer than ten, so there is no comparison to draw.
13 of the studies in Multiple Sclerosis with a site in Spain that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06141473Phase 3SanofiEfficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis | 2027-05-06 |
| NCT07325292Phase 3SanofiNon-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis | 2027-07-15 |
| NCT07735325University of SalamancaEffects of Sensorimotor Insoles on Stability and Gait in Patients With Multiple Sclerosis. | 2026-12 |
| NCT07152145Parc de Salut MarPilot Study of tSCS for Improving Upper Limb Function in People With Multiple Sclerosis | 2026-12 |
| NCT06968676Universidad Rey Juan CarlosMixed Reality for Upper Limb Rehabilitation in People With Multiple Sclerosis (VIRTUALDOMUS) | 2026-12-31 |
Add all 13 to your calendar (.ics) → With an account.
Among the 230 studies in Multiple Sclerosis with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to validate the safety and performance of the ABLE Exoskeleton device in people with multiple sclerosis during a 10-session gait training program in a clinical setting. Furthermore, the potential effects of the training on walking, and balance function, general health status, user satisfaction, and quality of life will be assessed.
This is a pre-post, single-center, quasi-experimental study with an estimated duration of 4 months since the approval date. The study will be conducted at the Fundación Esclerosis Múltiple de Madrid (FEMM), where a minimum of 20 participants are expected to be recruited over a maximum period of 2 months since the approval date.
After obtaining informed consent, through the Patient Information Sheet and the Informed Consent Form, the selection of the participants will be carried out to determine their inclusion in the study. Subjects who do not meet all the inclusion and exclusion criteria during the screening visit will be excluded from the study. At the latest, one week after the screening visit, the participants will undergo a preliminary assessment without the medical device.
Participants will undergo a 10-session training program with the ABLE Exoskeleton device for a maximum duration of 11 weeks. Sessions will be conducted 1 to 2 times per week, depending on the participant's availability. Each session will last approximately 60 minutes. During the training period, session data will be taken to assess the safety and clinical performance of the device. At the latest, one week after the last training session, a post-training assessment will be performed. Finally, two weeks after the last training session, a follow-up assessment will be made to the participants via a telephone call to review any adverse events (AE) reported between the end of the training and the follow-up.
This is the first study investigating the use of the ABLE Exoskeleton in people with MS, therefore the primary hypothesis of this study is that the ABLE Exoskeleton is safe and has adequate performance for the intended MS population in a clinical setting. The secondary hypothesis is that the device will have a positive impact on the muscular strength, spasticity, perceived rate of exertion, mobility, satisfaction, and quality of life of the study participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with MS will undergo a training program with the ABLE Exoskeleton device: a total of 10 sessions, distributed 1-2 sessions/week for up to 11 weeks.
Device: ABLE Exoskeleton
Participants with MS will undergo a training program with the ABLE Exoskeleton device: a total of 10 sessions, distributed 1-2 sessions/week for up to 11 weeks.
Number and type of device-related Adverse Events
To assess safety, the number of Severe Adverse Events (SAE), Adverse Events (AE) and drop-outs due to the device will be assessed and reported.
Time frame: Up to 16 weeks
Level of Assistance (LoA) to don/doff the device
Level of Assistance (LoA) to don/doff the device will be measured in every session. The level of assistance will be measured using a 6-item scale, from Total assistance to Independence, with Independence being the best outcome possible. Different assistance levels are defined taking into account the degree of participation of both the participant and the therapist on performing the activity.
Time frame: Up to 11 weeks
Time taken to don/doff the device
The time taken to don/doff the device will be measured in every session. Time will be measured in minutes and seconds for each activity. Donning time will start from the moment the participant is ready to transfer into the device until all the straps and clips are correctly tightened. Doffing time will start from the moment the participant starts taking off the device until they have completely removed it.
Time frame: Up to 11 weeks
Level of Assistance (LoA) to complete therapy activity tasks
Four therapy activity tasks will be attempted every session by the participant. The therapist will record the level of assistance required to complete each task during the session, using a 6-item scale, from Total assistance to Independence, with Independence being the best outcome possible. The tasks are the following: sit-to-stand, walk 10 meters, turn 180 degrees, and stand-to-sit.
Time frame: Up to 11 weeks
Time spent upright and time spent walking
In each training session, the time spent upright (in minutes) and the time spent walking (in minutes) with the device will be automatically measured and registered by the device.
Time frame: Up to 11 weeks
Number of steps walked
In each session, the number of steps taken (step count) with the device will be automatically measured and registered by the device.
Time frame: Up to 11 weeks
Distance walked
In each session, the distance walked (in meters) with the device will be automatically measured and registered by the device.
Time frame: Up to 11 weeks
Timed 25-Feet Walk test (T25FW)
The Timed 25-Foot Walk (T25FW) test measures the time a person needs to walk 25 feet. This test will be performed in the pre-post evaluations without the device to assess the change in the walking function after the training.
Time frame: Up to 11 weeks
Ambulation Index (AI)
The Ambulation Index (AI) is a rating scale that assesses mobility based on time and degree of assistance required when walking 25 feet as quickly as possible but safely. Scores range from 0 (asymptomatic and fully active) to 10 (bedridden). This test will be performed in the pre-post evaluations without the device to assess the change in the walking function after the training.
Time frame: Up to 11 weeks
6-Minute Walk Test (6MWT)
The 6-Minute Walk Test (6MWT) measures the distance a person can walk in 6 minutes. This test will be performed in the pre-post evaluations without the device to assess the change in the walking function after the training.
Time frame: Up to 11 weeks
Timed Up-and-Go test (TUG)
The Timed Up-and-Go Test (TUG) measures the time it takes a person to get up from a chair, walk 3 meters, turn around, and sit down again. This test will be performed in the pre-post evaluations without the device to assess the change in the walking function after the training.
Time frame: Up to 11 weeks
Trunk Impairment Scale (TIS)
The Trunk Impairment Scale (TIS) measures the motor impairment of the trunk through the evaluation of static and dynamic sitting balance as well as coordination of trunk movement. The total score ranges from 0 (minimal performance) to 23 (perfect performance). This test will be performed in the pre-post evaluations without the device to assess the change in the trunk impairment after training.
Time frame: Up to 11 weeks
Lower extremity muscle strenght
The Daniels Muscle Testing scale will be used to measure the strength of muscles in the lower extremities in the pre-post evaluations to assess motor function after the training. Scores range from 0 (absence of muscle activity) to 5 (normal muscle activity).
Time frame: Up to 11 weeks
Modified Ashworth Scale (MAS)
The Modified Ashworth Scale (MAS) measures spasticity in patients with lesions to the central nervous system. The scale assigns a grade of spasticity from 0 (no increase in muscle tone) to 4 (affected part rigid in flexion or extension). It will be evaluated in the pre-post evaluations without the device to assess the change in the spasticity after training.
Time frame: Up to 11 weeks
Borg Rating of Perceived Exertion
The Borg Rating of Perceived Exertion (RPE) scale is used to measure a person's perception of their effort and exertion, breathlessness, and fatigue during physical activity. Scores range from 6 (no exertion at all) to 20 (maximal exertion). It will be evaluated in the pre-post evaluations without the device to assess the change in the perceived exertion after the training.
Time frame: Up to 11 weeks
Barthel Index (BI) score
The Barthel Index (BI) will be used to assess the participants' ability to perform mobility and self-care activities of daily living (ADL). The total score ranges from 0 (total dependency) to 100 (independency). It will be evaluated in the pre-post evaluations without the device to assess the change in the independence to perform ADL after the training.
Time frame: Up to 11 weeks
Modified Fatigue Impact Scale (MFIS) score
The Modified Fatigue Impact Scale (MFIS) provides an assessment of the effects of fatigue in terms of physical, cognitive, and psychosocial functioning in persons with multiple sclerosis. The total score ranges from 0 to 84, with higher scores meaning a higher impact of fatigue. It will be evaluated in the pre-post evaluations without the device to assess the change in the fatigue after the training.
Time frame: Up to 11 weeks
Multiple Sclerosis Quality of Life-54 (MSQoL-54)
The Multiple Sclerosis Quality of Life-54 (MSQoL-54) is a multidimensional health-related quality of life (QoL) measure that combines both generic and MS-specific items into a single instrument. There is no single overall score for the MSQoL-54. Two summary scores - physical health and mental health - can be derived from a weighted combination of scale scores. The higher the score, the best the outcome. It will be evaluated in the pre-post evaluations without the device to assess the change in the QoL after the training.
Time frame: Up to 11 weeks
Psychosocial Impact of Assistive Devices Scale (PIADS) score
The Psychosocial Impact of Assistive Devices Scale (PIADS) is a 26-item, self-reported questionnaire that provides a measure of user perception and other psychological factors associated with assistive technology devices. Scores range from -78 (maximum negative impact) to +78 (maximum positive impact). It will be used to assess the effects of the ABLE Exoskeleton on functional independence, well-being, and quality of life of participants after the training program experience.
Time frame: Up to 11 weeks
Quebec User Evaluation of Satisfaction with assistive Technology (QUEST 2.0) score
The Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST 2.0) is a 12-item outcome measure that assesses user satisfaction with two components (Device and Services) using a 5-point scale ranging from 1 (not satisfied) to 5 (very satisfied). Only the 8 items referred to the device will be evaluated to measure user satisfaction from participants and therapists with the ABLE Exoskeleton after the training program experience.
Time frame: Up to 11 weeks
Ran from Apr 2024 to primary completion in Jul 2024, 3 months.
Of 874 interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's 3 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ABLE Human Motion S.L.